Developing novel ligands with enhanced binding affinity for the sphingosine 1-phosphate receptor 1 using machine learning

• URL: http://arxiv.org/abs/2307.16037v1
• Date: Sat, 29 Jul 2023 17:58:47 GMT
• Title: Developing novel ligands with enhanced binding affinity for the sphingosine 1-phosphate receptor 1 using machine learning
• Authors: Colin Zhang, Yang Ha
• Abstract summary: Multiple sclerosis (MS) is a debilitating neurological disease affecting nearly one million people in the United States. Siponimod, a ligand of S1PR1, was approved by the FDA in 2019 for MS treatment, but there is a demonstrated need for better therapies. This study demonstrates that machine learning can accelerate the drug discovery process and reveal new insights into protein-drug interactions.
• Score: 0.0
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Multiple sclerosis (MS) is a debilitating neurological disease affecting nearly one million people in the United States. Sphingosine-1-phosphate receptor 1, or S1PR1, is a protein target for MS. Siponimod, a ligand of S1PR1, was approved by the FDA in 2019 for MS treatment, but there is a demonstrated need for better therapies. To this end, we finetuned an autoencoder machine learning model that converts chemical formulas into mathematical vectors and generated over 500 molecular variants based on siponimod, out of which 25 compounds had higher predicted binding affinity to S1PR1. The model was able to generate these ligands in just under one hour. Filtering these compounds led to the discovery of six promising candidates with good drug-like properties and ease of synthesis. Furthermore, by analyzing the binding interactions for these ligands, we uncovered several chemical properties that contribute to high binding affinity to S1PR1. This study demonstrates that machine learning can accelerate the drug discovery process and reveal new insights into protein-drug interactions.

Related papers

• Enhancing Chemical Reaction and Retrosynthesis Prediction with Large Language Model and Dual-task Learning [8.402406301818905]
  Large language models (LLMs) have shown potential in many domains.<n>ChemDual is a novel framework for accurate chemical synthesis.<n>ChemDual achieves state-of-the-art performance in both predictions of reaction and retrosynthesis.
  arXiv  Detail & Related papers  (2025-05-05T13:31:36Z)
• MD-Syn: Synergistic drug combination prediction based on the multidimensional feature fusion method and attention mechanisms [0.0]
  Drug combination therapies have shown promising therapeutic efficacy in complex diseases and have demonstrated the potential to reduce drug resistance. The huge number of possible drug combinations makes it difficult to screen them all in traditional experiments. In this study, we proposed MD-Syn, a computational framework, which is based on the multidimensional feature fusion method and multi-head attention mechanisms.
  arXiv  Detail & Related papers  (2025-01-14T06:50:56Z)
• BatGPT-Chem: A Foundation Large Model For Retrosynthesis Prediction [65.93303145891628]
  BatGPT-Chem is a large language model with 15 billion parameters, tailored for enhanced retrosynthesis prediction. Our model captures a broad spectrum of chemical knowledge, enabling precise prediction of reaction conditions. This development empowers chemists to adeptly address novel compounds, potentially expediting the innovation cycle in drug manufacturing and materials science.
  arXiv  Detail & Related papers  (2024-08-19T05:17:40Z)
• Generative Active Learning for the Search of Small-molecule Protein Binders [87.106635995213]
  We introduce LambdaZero, a generative active learning approach to search for synthesizable molecules. LambdaZero learns to search over the vast space of molecules to discover candidates with a desired property. We apply LambdaZero with molecular docking to design novel small soluble molecules that inhibit the enzyme Epoxide Hydrolase 2 (sEH) LambdaZero discovers novel scaffolds of synthesizable, drug-like inhibitors for sEH.
  arXiv  Detail & Related papers  (2024-05-02T16:39:21Z)
• Multi-objective generative AI for designing novel brain-targeting small molecules [0.20088541799100385]
  We use multi-objective generative AI to synthesize drug-like BBB-permeable small molecules. Specifically, we computationally synthesize molecules with predicted binding affinity against dopamine receptor D2. We design a library of 26,581 novel and diverse small molecules containing hits with high predicted BBB permeability and favorable predicted safety and toxicity profiles.
  arXiv  Detail & Related papers  (2024-04-16T12:57:06Z)
• Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks [0.0]
  We propose an end to end generative system, DrugGEN, for the de novo design of drug candidate molecules.<n>The system is trained using a large dataset of drug like compounds and target specific bioactive molecules.<n>It is possible to easily train models for other druggable proteins, given a dataset of experimentally known bioactive molecules.
  arXiv  Detail & Related papers  (2023-02-15T18:59:27Z)
• Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model [4.815696666006742]
  Structure-based de novo method can overcome the data scarcity of active by incorporating drug-target interaction into deep generative architectures. Here, we demonstrate a widely used and fast protein sequence-based reinforcement learning model for drug discovery. As a proof of concept, the RL model was utilized to design molecules for four targets.
  arXiv  Detail & Related papers  (2022-08-14T10:41:52Z)
• A Ligand-and-structure Dual-driven Deep Learning Method for the Discovery of Highly Potent GnRH1R Antagonist to treat Uterine Diseases [12.616493352225909]
  Gonadotrophin-releasing hormone receptor (GnRH1R) is a promising therapeutic target for the treatment of uterine diseases. To fill this gap, we aim to develop a deep learning-based framework to facilitate the discovery of a new orally active small-molecule drug targeting GnRH1R with desirable properties.
  arXiv  Detail & Related papers  (2022-07-23T16:04:54Z)
• LIMO: Latent Inceptionism for Targeted Molecule Generation [14.391216237573369]
  We present Latent Inceptionism on Molecules (LIMO), which significantly accelerates molecule generation with an inceptionism-like technique. Comprehensive experiments show that LIMO performs competitively on benchmark tasks. One of our generated drug-like compounds has a predicted $K_D$ of $6 cdot 10-14$ M against the human estrogen receptor.
  arXiv  Detail & Related papers  (2022-06-17T21:05:58Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Neural networks for Anatomical Therapeutic Chemical (ATC) [83.73971067918333]
  We propose combining multiple multi-label classifiers trained on distinct sets of features, including sets extracted from a Bidirectional Long Short-Term Memory Network (BiLSTM) Experiments demonstrate the power of this approach, which is shown to outperform the best methods reported in the literature.
  arXiv  Detail & Related papers  (2021-01-22T19:49:47Z)
• Confidence-guided Lesion Mask-based Simultaneous Synthesis of Anatomic and Molecular MR Images in Patients with Post-treatment Malignant Gliomas [65.64363834322333]
  Confidence Guided SAMR (CG-SAMR) synthesizes data from lesion information to multi-modal anatomic sequences. module guides the synthesis based on confidence measure about the intermediate results. experiments on real clinical data demonstrate that the proposed model can perform better than the state-of-theart synthesis methods.
  arXiv  Detail & Related papers  (2020-08-06T20:20:22Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.